received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) in treating Covid-19 patients. PNB 001 may be the first new chemical entity in the world for treating
The phase 2 clinical trials will be completed in 60 days. The study will be conducted in 40 Covid-19 positive patients at BMJ Medical College, Pune, who are moderate patients on oxygen support. The effect of PNB 001will be compared with Dexamethasone, currently the most popular medicine in Covid-19 treatment in the world. A larger population, approximately 350, of Covid-19 patients will be enrolled across the country in six medical colleges the phase 3 clinical trials after reviewing the phase 2 clinical trial results.
